at which students and postdocs will have the opportunity to present posters and discuss their research with colleagues. The Fair will promote the formation of new connections among faculty and ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

Results from GALILEO-1, a first in human clinical trial of FLT201 AAV-gene therapy in adult patients with Gaucher disease type 1 (Poster #318) Session: Poster Session III Date & Time: Thursday, ...